NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Seer, Inc. (SEER) Stock Analysis

Seer, Inc. (SEER) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SEER

$2.03

+$0.05 (+2.53%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SEER with… →

SEER Key Statistics

As of Oct 21, 2026
Trading
Open
$1.97
Previous Close
$1.98
Day's Range
1.97–2.10
52-Week Range
1.55–2.41
Volume
121.99K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.47
Valuation
Market Cap
$112.41M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.91
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.22
Financials (FY)
Revenue (FY)
$16.12M+15.57%
Net Income (FY)
−$73.60M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
55.37M
1-Year Return
−6.45%
Dividend and dates
Earnings Date
November 10, 2026
Avg Volume
455.83K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SEER closed at $2.03, −6.45% over 1 year.

Seer, Inc. (SEER) has a market capitalization of $112.41M.

In fiscal 2025, SEER reported revenue of $16.12M.

SEER Stock Return by Calendar Year

Seer, Inc. (SEER) return since Dec 2020: what $10,000 became

1 year
$10,000 $9,355
−6.45%
5 years
$10,000 $589
−94.11%
Since Dec 2020
$10,000 $360
−96.40%

If you had invested $10,000 in Seer, Inc. (SEER) at the close on December 4, 2020, the earliest close on record here, it would have been worth $360 at the close on October 21, 2026: −96.40% in total, −43.21% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+10.93%
2025−20.78%
2024+19.07%
2023−66.55%
2022−74.57%
2021−59.37%
2020 (partial year)−0.57%

As of October 21, 2026.

SEER Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$16.12M−$73.60M−456.6%
2024$13.95M−$86.60M−620.9%
2023$15.18M−$86.28M−568.3%
2022$14.69M−$92.97M−633.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$16.12M$8.01M−$77.99M−$73.60M−456.6%
2024$13.95M$6.83M−$100.10M−$86.60M−620.9%
2023$15.18M$7.03M−$103.46M−$86.28M−568.3%
2022$14.69M$6.29M−$97.24M−$92.97M−633.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SEER Valuation vs Biotechnology Median

Median of 608 stocks
MetricSEERBiotechnology medianvs median
P/S ratio7.9113.3041% below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Seer, Inc. (SEER) is capitalised at $112.41M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 124.

Over the past 52 weeks the price has ranged from $1.55 to $2.41. The most recent close on file for SEER is $2.03, dated October 21, 2026. That is +$0.05 (+2.53%) against the previous close. The latest close sits 30.97% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $16.12M. Against the prior fiscal year total of $13.95M, that is a change of +15.57%. The same year closed with a net loss of $73.60M. Earnings per share on a trailing basis come to −1.22.

Across the 4 fiscal years on file, revenue moves from $14.69M in 2022 to $16.12M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 7.91. On price-to-sales that is 40.55% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −6.45%. Measured over 5 years, that is −43.25% a year compounded. Beta against the wider market is reported at 1.47. Annualized volatility over the trailing 5 years is 73.74%.

Growth & Income

The record shows no dividend for SEER.

2026 is still running; the total return is +10.93% year to date. The strongest complete calendar year on file is 2024 at +19.07%; the weakest is 2022 at −74.57%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Seer, Inc. (SEER) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Seer, Inc. SEER $112.41M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Seer, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Seer, Inc.

Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Visit website →